The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
India’s pharmaceutical sector stands at a pivotal inflection point
Elanco expects Befrena to launch in the US in the first half of 2026
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Expands bioprocessing footprint across Asia
Subscribe To Our Newsletter & Stay Updated